Related Experiment Video
Updated: Aug 23, 2026

Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Selective modulation of microglial signal transduction by PACAP
1Department of Pharmacology, School of Medicine, Kyungpook National University, #101 Dong-In, Joong-gu, Daegu, 700-422 Korea.
Abstract:
We have investigated the possible effect of pituitary adenylate cyclase-activating polypeptide (PACAP) on signal transduction pathways associated with inflammatory activation of BV-2 mouse microglia cells. Pretreatment of the cells with PACAP resulted in a significant decrease in LPS- or IFNgamma-induced NO production as well as iNOS and IL-1beta mRNA levels. The inhibitory effect of PACAP appeared to be mediated through an increase in intracellular cAMP. PACAP inhibition of LPS-induced NO production was accompanied by inhibition of p38 MAPK activation, but not ERK, JNK, or NF-kappaB. IFNgamma-induced STAT-1 activation or IRF-1 induction was not significantly influenced by PACAP. Therefore, PACAP appears to suppress inflammatory activation of BV-2 microglia via specific inhibition of LPS-induced p38 MAPK pathway.
Insights
Pituitary adenylate cyclase-activating polypeptide (PACAP) reduces inflammatory responses in mouse microglia cells. PACAP inhibits nitric oxide production and inflammatory gene expression by modulating specific signaling pathways.
Area of Science:
- Neuroimmunology
- Cellular signaling
- Molecular biology
Background:
- Microglia play crucial roles in neuroinflammation.
- Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neuropeptide with known immunomodulatory functions.
- Understanding PACAP's effects on microglial inflammatory pathways is essential for neuroinflammatory disease research.
Purpose of the Study:
- To investigate the impact of PACAP on inflammatory signaling pathways in BV-2 mouse microglia cells.
- To elucidate the specific molecular mechanisms underlying PACAP's anti-inflammatory effects.
Main Methods:
- BV-2 mouse microglia cells were pretreated with PACAP.
- Cells were stimulated with lipopolysaccharide (LPS) or interferon-gamma (IFN-gamma).
- Nitric oxide (NO) production, inducible nitric oxide synthase (iNOS) and Interleukin-1 beta (IL-1beta) mRNA levels, and key signaling pathway activations (p38 MAPK, ERK, JNK, NF-kappaB, STAT-1, IRF-1) were assessed.
Main Results:
- PACAP pretreatment significantly decreased LPS- or IFN-gamma-induced NO production.
- PACAP reduced iNOS and IL-1beta mRNA levels.
- PACAP's inhibitory effect was linked to increased intracellular cyclic adenosine monophosphate (cAMP).
- PACAP specifically inhibited LPS-induced p38 mitogen-activated protein kinase (MAPK) activation, without affecting ERK, JNK, or NF-kappaB.
- IFN-gamma-induced STAT-1 activation and IRF-1 induction were not significantly influenced by PACAP.
Conclusions:
- PACAP suppresses inflammatory activation in BV-2 microglia.
- The anti-inflammatory effects of PACAP are mediated through increased intracellular cAMP.
- PACAP specifically inhibits the LPS-induced p38 MAPK pathway in microglia, suggesting a targeted mechanism for controlling neuroinflammation.